DUBLIN–(BUSINESS WIRE)–The “Sensorineural Hearing Loss – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The “Sensorineural Hearing Loss – Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Sensorineural Hearing Loss pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Sensorineural Hearing Loss commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sensorineural Hearing Loss collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Companies and academics are working to assess challenges and seek opportunities that could influence Sensorineural Hearing Loss R&D. The therapies under development are focused on novel approaches to treat/improve Sensorineural Hearing Loss.
Sensorineural Hearing Loss Emerging Drugs Chapters
This segment of the Sensorineural Hearing Loss report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sensorineural Hearing Loss Emerging Drugs
PIPE 505: Pipeline Therapeutics
PIPE-505, is Pipeline Therapeutics proprietary, locally delivered, gamma secretase inhibitor that targets two key regenerative pathways in the cochlea, the Netrin/DCC pathway for synaptic regeneration and the Notch pathway for outer hair cell regeneration. These pathways are linked to the two main areas of deficient auditory function in Sensorineural Hearing loss, intelligibility, and audibility, respectively.
LY 3056480: Audion Therapeutics
Audion’s lead candidate (LY 3056480) has undergone a thorough and extensive preclinical characterization in multiple model systems prior to initiation of the clinical studies. These studies include effects of the drug on damaged inner ear tissue, inner ear PK studies to determine drug exposure using different formulations and formal ototoxicity studies to exclude toxic effects on normal hair cells and inner ear tissues. The lead candidate (LY 3056480) has now completed clinical Phase 1 and Phase 2 testing, and delivered encouraging results that supported the advancement into Phase 2b studies.
OTO 413: Otonomy
OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in development for the treatment of hearing loss. In December 2020, Otonomy, announced positive top-line results from a Phase 1/2 clinical trial of OTO-413, demonstrating that a single intratympanic injection of OTO-413 was well-tolerated and showed therapeutic activity across multiple speech-in-noise hearing tests. Otonomy is currently conducting a Phase 2a clinical trial for OTO-413, with top-line results expected early in the second quarter of 2022, and are also evaluating the safety of higher dosing.
Sensorineural Hearing Loss: Therapeutic Assessment
This segment of the report provides insights about the different Sensorineural Hearing Loss drugs segregated based on the following parameters that define the scope of the report, such as:
Major Players in Sensorineural Hearing Loss
There are approx. 15+ key companies which are developing the therapies for Sensorineural Hearing Loss. The companies which have their Sensorineural Hearing Loss drug candidates in the most advanced stage, i.e. phase II include, Audion Therapeutics.
Key Players
- Pipeline Therapeutics
- Audion Therapeutics
- Otonomy
- Sound Pharmaceuticals
- Decibel Therapeutics
- Frequency Therapeutics
- Acousia Therapeutics
- Sensorion
- Altamira Therapeutics
- Sound Pharmaceuticals
Key Products
- DB-OTO
- FX 322
- Otopotin
- Arazasetron
- PIPE-505
- LY 3056480
- OTO 413
- DB 104
- Brimapitide
- Ebselen
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/nukn1h
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900